3rd Feb 2012 15:22
PuriCore plc
Directors Dealings and Share Option Grants
MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 3 February 2012 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, announces today directors dealings and share option grants, in accordance with the Disclosure and Transparency Rules.
Director Dealings
The Company announces that on 1 February 2012 the following Director purchased shares in the Company, as set out below.
Name
| Number of shares purchased | Purchase price of shares | Shareholding following the acquisition | % of issued share capital |
Gregory Todd Bosch, Executive Director | 100,000 | 65p | 180,000 | 0.71% |
Non-Executive Director Share Option Grants
PuriCore also announces it has issued share options to the Company's Non-Executive Directors as set forth below. The share options have an exercise price of 61.43p, which is five per cent over the closing market price of the Company's ordinary shares on 2 February 2012, and a five-year term.
Name | Number of share options granted | Vesting |
William Birkett, Senior Independent Non-Executive Director | 70,000 | Immediate |
Matthew Hammond, Non-Executive Director | 35,000 | Immediate |
Michael Sapountzoglou, Non-Executive Director | 35,000 | Immediate |
Michael Ashton, Independent Non-Executive Director | 35,000* | Half on 2 February 2013; half on 2 February 2014 |
*As announced 1 February 2012.
Enquiries:
FTI Consulting | +44 (0) 20 7831 3113 |
Susan Quigley | |
Ben Brewerton |
About PuriCore
PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology offers a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. PuriCore's Solutions are proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.
Related Shares:
RLM.L